We are seeing patients in-person and through Video Visits. Learn more about how we’re keeping you safe and please review our updated visitor policy. Please also consider supporting Weill Cornell Medicine’s efforts to support our front-line workers.
Sandra and Edward Meyer Cancer Center

Warning message

The subscription service is currently unavailable. Please try again later.

You are here


Expert discusses emerging agents and the future of follicular lymphoma

Monday, January 18, 2016

John Leonard, M.D.John Leonard, M.D.

Indolent lymphoma accounts for approximately 30 percent of patients with non-Hodgkin lymphoma (NHL)., medical oncology, at Weill Cornell Medicine and NewYorkPresbyterian Hospital.

“When patients relapse after initial therapy, the key factors in choosing a treatment include the time from first therapy, the time to reoccurrence, how sick they are, their age, and what they need in terms of symptom relief at that time,” says Leonard.

Standard treatment options include single-agent rituximab (Rituxan) and chemotherapy with rituximab. However, a number of new approaches for indolent lymphoma and more are on the horizon, Leonard says.

In an interview with OncLive, Leonard discusses the potential for lenalidomide (Revlimid), idelalisib (Zydelig), and ibrutinib (Imbruvica) in follicular lymphoma, possible combination therapies, and challenges that remain in the treatment of the disease.